Publications
Abou-Alfa GK, Geyer SM, Nixon AB, Innocenti F, Shi Q, Kumthekar P, Jacobson S, El Dika I, Yaqubie A, Lopez J, Huang B, Tang YW, Wen Y, Schwartz LH, El-Khoueiry AB, Knox JJ, Rajdev L, Bertagnolli MM, Meyerhardt JA, O'Reilly EM, Venook AP. CCALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C infection in Patients with advanced hepatocellular carcinoma. Cancer Research Communications. 2024. PMID: 38363156
Walmsley CS, Jonsson P, Cheng ML, McBride S, Kaeser C, Vargas HA, Laudone V, Taylor BS, Kappagantula R, Baez P, Richards AL, Noronha AM, Perera D, Berger M, Solit DB, Iacobuzio-Donahue CA, Scher HI, Donoghue MTA, Abida W, Schram AM. Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy. NPJ precision oncology. 2024. PMID: 38355834
Yau T, Kaseb A, Cheng AL, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Milwee S, Wang Z, Curran D, Kelley RK, Rimassa L. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study. The lancet. Gastroenterology & hepatology. 2024. PMID: 38364832
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Author Correction: Hepatocellular carcinoma. Nature reviews. Disease primers. 2024. PMID: 38346997
Wise DR, Pachynski RK, Denmeade SR, Aggarwal RR, Deng J, Febles VA, Balar AV, Economides MP, Loomis C, Selvaraj S, Haas M, Kagey MH, Newman W, Baum J, Troxel AB, Griglun S, Leis D, Yang N, Aranchiy V, Machado S, Waalkes E, Gargano G, Soamchand N, Puranik A, Chattopadhyay P, Fedal E, Deng FM, Ren Q, Chiriboga L, Melamed J, Sirard CA, Wong KK. A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Prostate cancer and prostatic diseases. 2024. PMID: 38341461
Arai H, Yang Y, Baca Y, Millstein J, Denda T, Ou FS, Innocenti F, Takeda H, Kubota Y, Doi A, Horie Y, Umemoto K, Izawa N, Wang J, Battaglin F, Jayachandran P, Algaze S, Soni S, Zhang W, Goldberg RM, Hall MJ, Scott AJ, Hwang JJ, Lou E, Weinberg BA, Marshall J, Goel S, Xiu J, Michael Korn W, Venook AP, Sunakawa Y, Lenz HJ. Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer. European journal of cancer (Oxford, England : 1990). 2024. PMID: 38359495
Lara MS, Blakely CM, Riess JW. Targeting MEK in non-small cell lung cancer. Current problems in cancer. 2024. PMID: 38341356
Palmieri C, Linden H, Birrell SN, Wheelwright S, Lim E, Schwartzberg LS, Dwyer AR, Hickey TE, Rugo HS, Cobb P, O'Shaughnessy JA, Johnston S, Brufsky A, Tilley WD, Overmoyer B. Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinatio The Lancet. Oncology. 2024. PMID: 38342115
Gu D, Rafferty H, Vijayaraghavan M. Factors Associated with Smoking Cessation and the Receipt of Cessation Services in a Public, Safety-Net Primary Care System. Journal of general internal medicine. 2024. PMID: 38332442
Haugh A, Daud AI. Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma. American journal of clinical dermatology. 2024. PMID: 38329690
Loeb S, Sanchez Nolasco T, Byrne N, Allen L, Langford AT, Ravenell J, Gomez SL, Washington SL, Borno HT, Griffith DM, Criner N. Representation Matters: Trust in Digital Health Information Among Black Patients With Prostate Cancer. The Journal of urology. 2024. PMID: 38329047
Rodriguez-Otero P, van de Donk NWCJ, Pillarisetti K, Cornax I, Vishwamitra D, Gray K, Hilder B, Tolbert J, Renaud T, Masterson T, Heuck C, Kane C, Verona R, Moreau P, Bahlis N, Chari A. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood cancer journal. 2024. PMID: 38307865
Meattini I, Becherini C, Caini S, Coles CE, Cortes J, Curigliano G, de Azambuja E, Isacke CM, Harbeck N, Kaidar-Person O, Marangoni E, Offersen BV, Rugo HS, Salvestrini V, Visani L, Morandi A, Lambertini M, Poortmans P, Livi L, Consensus Panellist Group. International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations. The Lancet. Oncology. 2024. PMID: 38301705
Motzer RJ, Jonasch E, Agarwal N, Alva A, Bagshaw H, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Gunn A, Haas N, Johnson M, Kapur P, King J, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Sweis R, Zibelman M, Schonfeld R, Stein M, Gurski LA. NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024. Journal of the National Comprehensive Cancer Network : JNCCN. 2024. PMID: 38394781
Daniel H Kwon, Lauren Trihy, Eliza Hearst, Nika Darvish, Gurleen Kaur, Samantha Nesheiwat, Hala Borno, Rohit Bose, Jonathan Chou, Ivan de Kouchkovsky, Arpita Desai, Kelly N. Fitzgerald, Lawrence Fong, Terence W. Friedlander, Vadim S Koshkin, Eric J. Small, Rahul Raj Aggarwal, Jeffrey Belkora. Implementing consultation audio recording applications to improve informed decision-making (IDM) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) eligible for docetaxel. Journal of Clinical Oncology. 2024. PMID:
Zussman JW, Ma JY, Bindman JG, Cornes S, Davis JA, Brondfield S. Identifying Strategies for the Use of Gender and Sex Language in Clinical One-Liners. LGBT health. 2024. PMID: 38301142
Kelley RK. Durvalumab Plus Tremelimumab for First-Line Treatment of Hepatocellular Carcinoma. Gastroenterology & hepatology. 2024. PMID: 38414909
Vadim S Koshkin, Tanya Jindal, Jun Yan He, Li Zhang, Celine N. Galang, Divya Natesan, Vipul Kumar, Xiaolin Zhu, Jonathan Chou, Rahul Raj Aggarwal, Eric J. Small, Maxwell Meng, Sima P. Porten, David Yoonsuk Oh, Lawrence Fong, Terence W. Friedlander. Efficacy outcomes and biomarker analysis from phase II trial of escalating doses of neoadjuvant atezolizumab in patients with muscle-invasive urothelial carcinoma ineligible for cisplatin-based chemotherapy. Journal of Clinical Oncology. 2024. PMID:
Shah NP, Bhatia R, Altman JK, Amaya M, Begna KH, Berman E, Chan O, Clements J, Collins RH, Curtin PT, DeAngelo DJ, Drazer M, Maness L, Metheny L, Mohan S, Moore JO, Oehler V, Pratz K, Pusic I, Rose MG, Shomali W, Smith BD, Styler M, Talpaz M, Tanaka TN, Tantravahi S, Thompson J, Tsai S, Vaughn J, Welborn J, Yang DT, Sundar H, Gregory K. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2024. PMID: 38394770
Wu C, Mulakaluri A, Chaurasia P, Suryanarayana S, Singh A, Krauss N, Tahir P, Elder C, Puthiyedath R, Dhruva A. A scoping review of Ayurvedic rasayana adaptogens in oncology. Journal of Ayurveda and integrative medicine. 2024. PMID: 38301299